4142 fundamentals
Key facts
Market capitalization—
Founded—
CEO—
Website—
About
Adimmune Corp. engages in the manufacturing and sales of influenza vaccine. Its products include Trivalent Influenza vaccine, Tetravalent Influenza vaccine, Influenza A (H1N1) Virus Monovalent Vaccine, Japanese Encephalitis Vaccine (JEV), and Tetanus toxoid, and purified Tuberculin. Its business scope includes research and development, processing, manufacturing, and trading of serum, vaccines, test reagents, biological agents and their bacterial liquids, and raw materials. The company was founded on December 22, 1965 and is headquartered in Taichung, Taiwan.
Valuation
Fundamental metrics to determine fair value of the stock
Growth and Profitability
Company’s recent performance and margins
Dividends
Dividend yield, history and sustainability
No dividends
4142 has never paid dividends and has no current plans to do so.
Financial health
Financial position and solvency of the company